{
  "id": "5c58a92386df2b917400000e",
  "type": "summary",
  "question": "What is the mechanism of action of Emicizumab?",
  "ideal_answer": "Emicizumab (Hemlibra\u00ae) is a bispecific humanized monoclonal antibody that restores the function of missing activated FVIII by bridging activated FIX and FX to facilitate effective haemostasis in patients with haemophilia A.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27405674",
    "http://www.ncbi.nlm.nih.gov/pubmed/30462521",
    "http://www.ncbi.nlm.nih.gov/pubmed/27223146",
    "http://www.ncbi.nlm.nih.gov/pubmed/29734520",
    "http://www.ncbi.nlm.nih.gov/pubmed/30264916",
    "http://www.ncbi.nlm.nih.gov/pubmed/28451690",
    "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
    "http://www.ncbi.nlm.nih.gov/pubmed/29296836",
    "http://www.ncbi.nlm.nih.gov/pubmed/30431213",
    "http://www.ncbi.nlm.nih.gov/pubmed/30125997",
    "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
    "http://www.ncbi.nlm.nih.gov/pubmed/29769259",
    "http://www.ncbi.nlm.nih.gov/pubmed/30344994",
    "http://www.ncbi.nlm.nih.gov/pubmed/29888855",
    "http://www.ncbi.nlm.nih.gov/pubmed/29214439",
    "http://www.ncbi.nlm.nih.gov/pubmed/30278802",
    "http://www.ncbi.nlm.nih.gov/pubmed/27384849",
    "http://www.ncbi.nlm.nih.gov/pubmed/29645406",
    "http://www.ncbi.nlm.nih.gov/pubmed/29357074",
    "http://www.ncbi.nlm.nih.gov/pubmed/30444568"
  ],
  "snippets": [
    {
      "text": "Emicizumab-kxwh (Hemlibra\u00ae) is a bispecific humanized monoclonal antibody that restores the function of missing activated FVIII by bridging activated FIX and FX to facilitate effective haemostasis in patients with haemophilia A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357074",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Emicizumab (ACE910) is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29214439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UMMARY: Background Emicizumab is an anti-activated factor\u00a0IX/FX bispecific antibody that mimics activated FVIII cofactor function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29645406",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging bypass agents including zymogen-like factor IXa and Xa molecules are in development and a bispecific antibody, emicizumab, demonstrated efficacy in a phase 3 trial in people with hemophilia A and inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29769259",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY: Background Emicizumab is an anti-factor (F)IXa/X bispecific monoclonal antibody (mAb), mimicking the factor (F)VIIIa cofactor activity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29734520",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Safety concerns may exist when combining emicizumab with bypassing agents. Combined bypassing agent and bispecific antibody increased thrombin generation up to 17-fold. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29888855",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}